Step 1 of 2
Explore current and emerging phase III evidence for TROP2 ADCs in patients with metastatic triple-negative breast cancer who are ineligible for immunotherapy, including implications for patients and healthcare teams when selecting first-line and later-line treatments. Examine how patient characteristics, prior treatment exposure, comorbidities, and distinct adverse event profiles inform individualized care, along with multidisciplinary strategies for toxicity prevention, monitoring, supportive care, and dose modification.